Aerovate completes Phase 2b enrollment (202 patients) and enrolls first Phase 3 patient in AV-101 PAH trial

Jade Biosciences, Inc.

Phase 2b portion of IMPAHCT trial enrolled 202 adult patients with PAH.
First patient enrolled in Phase 3 portion under adaptive trial design.
Topline Phase 2b data expected in June 2024.
Over 120 sites actively recruiting for Phase 3 globally.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.